Health economic analysis of ticagrelor in patients with acute coronary syndromes intended for non-invasive therapy.

ABSTRACT:

Objective

To investigate the cost effectiveness of ticagrelor versus clopidogrel in patients with acute coronary syndromes (ACS) in the Platelet Inhibition and Patient Outcomes (PLATO) study who were scheduled for non-invasive management.

Methods

A previously developed cost effectiveness model was used to estimate long-term costs and outcomes for patients scheduled for non-invasive management. Healthcare costs, event rates and health-related quality of life under treatment with either ticagrelor or clopidogrel over 12 months were estimated from the PLATO study. Long-term costs and health outcomes were estimated based on data from PLATO and published literature sources. To investigate the importance of different healthcare cost structures and life expectancy for the results,

SUBMITTER: Janzon M 

PROVIDER: S-EPMC4316918 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature